Trial NCT03704714

View at ClinicalTrials.gov 
Org. Study IDs: NU 17H08
Secondary IDs: NCI-2018-01666 NU 17H08 P30CA060553 STU00207793

Last trial update was posted on 2022-08-15

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Cortisone Cyclophosphamide Doxorubicin Immunoglobulins Liposomal doxorubicin Nivolumab Prednisone Rituximab Vincristine

MeSH Conditions

Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin

Other Conditions

Aggressive Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma CD20 Positive Diffuse Large B-Cell Lymphoma Unclassifiable Intravascular Large B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Stopping Reasons

Protocol being amended for stats/accrual changes as per PI

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID